P-PDL1-CP

**P-PDL1-CP** is a preclinical, tumor-acidity-activatable macromolecular nanodrug developed for prostate cancer immunotherapy. It consists of a lysosome-disrupting poly(2-diisopropylaminoethyl methacrylate) core, long-chain polyethylene glycol coating, and surface-conjugated anti-programmed cell death 1 ligand 1 antibody linked through an acidity-labile bond. In the acidic tumor microenvironment, the construct releases anti-programmed cell death 1 ligand 1 antibody to relieve programmed cell death 1 ligand 1-mediated immune suppression, while the residual poly(2-diisopropylaminoethyl methacrylate) nanoparticle undergoes a charge switch, is taken up by tumor cells, disrupts lysosomal function, and blocks autophagic flux. This increases major histocompatibility complex class I expression and tumor susceptibility to cytotoxic T cells and tumor necrosis factor alpha. In mouse prostate-cancer models, P-PDL1-CP enhanced dendritic-cell maturation, tumor-infiltrating cytotoxic T cells, intratumoral tumor necrosis factor alpha and interferon gamma, and antitumor immune memory. ([europepmc.org](https://europepmc.org/article/MED/37474083))

Other names

P-PDL1-CPP-PDL-1-CPP-PDL 1-CP